Predictive Oncology Inc.Predictive Oncology Inc.Predictive Oncology Inc.

Predictive Oncology Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪4.97 M‬USD
−3.0596USD
‪−13.98 M‬USD
‪1.78 M‬USD
‪6.52 M‬
Beta (1Y)
2.15
Employees (FY)
34
Change (1Y)
0
Revenue / Employee (1Y)
‪52.36 K‬USD
Net income / Employee (1Y)
‪−411.29 K‬USD

About Predictive Oncology Inc.


CEO
Raymond F. Vennare
Headquarters
Pittsburgh
Founded
2002
FIGI
BBG000PVXTF7
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of POAI is 0.7500 USD — it has increased by 8.75% in the past 24 hours. Watch Predictive Oncology Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Predictive Oncology Inc. stocks are traded under the ticker POAI.
POAI stock has risen by 0.81% compared to the previous week, the month change is a 8.12% rise, over the last year Predictive Oncology Inc. has showed a −77.41% decrease.
POAI reached its all-time high on Aug 27, 2013 with the price of 176,691.8000 USD, and its all-time low was 0.5500 USD and was reached on Oct 15, 2024. View more price dynamics on POAI chart.
See other stocks reaching their highest and lowest prices.
POAI stock is 2.66% volatile and has beta coefficient of 2.15. Track Predictive Oncology Inc. stock price on the chart and check out the list of the most volatile stocks — is Predictive Oncology Inc. there?
Today Predictive Oncology Inc. has the market capitalization of ‪4.97 M‬, it has increased by 2.19% over the last week.
Yes, you can track Predictive Oncology Inc. financials in yearly and quarterly reports right on TradingView.
Predictive Oncology Inc. is going to release the next earnings report on Apr 8, 2025. Keep track of upcoming events with our Earnings Calendar.
POAI earnings for the last quarter are −0.48 USD per share, whereas the estimation was −0.32 USD resulting in a −50.00% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Predictive Oncology Inc. earnings.
Predictive Oncology Inc. revenue for the last quarter amounts to ‪345.69 K‬ USD, despite the estimated figure of ‪500.00 K‬ USD. In the next quarter, revenue is expected to reach ‪350.00 K‬ USD.
POAI net income for the last quarter is ‪−3.09 M‬ USD, while the quarter before that showed ‪−3.18 M‬ USD of net income which accounts for 2.72% change. Track more Predictive Oncology Inc. financial stats to get the full picture.
No, POAI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 34.00 employees. See our rating of the largest employees — is Predictive Oncology Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Predictive Oncology Inc. EBITDA is ‪−12.72 M‬ USD, and current EBITDA margin is −740.52%. See more stats in Predictive Oncology Inc. financial statements.
Like other stocks, POAI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Predictive Oncology Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Predictive Oncology Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Predictive Oncology Inc. stock shows the sell signal. See more of Predictive Oncology Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.